In re: VITAL PHARMACEUTICALS, INC., et al. v. JOHN H. OWOG, et al.

CourtUnited States Bankruptcy Court, S.D. Florida.
DecidedMarch 24, 2026
Docket24-01009
StatusUnknown

This text of In re: VITAL PHARMACEUTICALS, INC., et al. v. JOHN H. OWOG, et al. (In re: VITAL PHARMACEUTICALS, INC., et al. v. JOHN H. OWOG, et al.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. Florida. primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: VITAL PHARMACEUTICALS, INC., et al. v. JOHN H. OWOG, et al., (Fla. 2026).

Opinion

Sr Ma, ey * AO OW ae if * A iD 8 Ss 74 □□□ a wilky & — <3 a8

ORDERED in the Southern District of Florida on March 23, 2026.

Peter D. Russin, Judge United States Bankruptcy Court

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF FLORIDA FORT LAUDERDALE DIVISION In re: Chapter 11 Case

VITAL PHARMACEUTICALS, INC., et al., Case No. 22-17842-PDR Debtors. ef VPX LIQUIDATING TRUST, Plaintiff, Adv. Pro. No. 24-01009-PDR Vv.

JOHN H. OWOG, et al., Defendants. ef

Page 1 of 33

ORDER GRANTING LIQUIDATING TRUST’S MOTION FOR PARTIAL SUMMARY JUDGMENT ON COUNT THREE AND DENYING DEFENDANT’S CROSS-MOTION FOR SUMMARY JUDGMENT Corporate officers who breach their fiduciary duties do not become immune from accountability simply because they are also the only stockholders. Florida law imposes fiduciary obligations on directors and officers for the protection of the corporation itself—not for the benefit of any particular class of shareholders, and not subject to waiver by a sole owner who later finds it convenient to argue that no one was harmed but himself. When those obligations are breached and the corporation is driven into bankruptcy, the right to enforce them passes to the trustee or liquidating trust.

The question before the Court is whether John H. Owoc—VPX’s founder, sole shareholder, sole director, and CEO—breached his fiduciary duties to the corporation by orchestrating a false advertising campaign that a federal jury found to be willful

and deliberate, resulting in a judgment approaching $300 million. The Liquidating Trust argues that he did and moves for partial summary judgment on Count Three of its Second Amended Complaint.1 Mr. Owoc opposes and raises a Cross-Motion for Summary Judgment embedded in his Response.2 For the reasons that follow, the Liquidating Trust’s Motion is granted, and Mr. Owoc’s Cross-Motion is denied. I. Background

1Dkt. No. 364. 2Dkt. No. 384. Mr. Owoc founded Vital Pharmaceuticals, Inc. (“VPX”) in 1993, serving as its sole officer and shareholder.3 Under his leadership, VPX experienced significant growth and commercial success with its Bang energy drink brand.4 At its peak, the

company generated over $1 billion in annual revenue—an extraordinary achievement by any measure.5 However, central to Bang’s commercial success were marketing claims about a proprietary ingredient Mr. Owoc called “Super Creatine.” VPX marketed Super Creatine as a superior form of creatine that provided significant physical and mental health benefits.6 Those claims, as a federal jury would later find, were false.7 The

Complaint in this adversary proceeding refers to the false advertising as the “Super Creatine Scheme.”8 It is undisputed—and the Defendant has expressly acknowledged in his briefing and sworn declaration—that Mr. Owoc was VPX’s sole shareholder, sole

3Declaration of John H. Owoc (Dkt. No. 384) at ¶¶ 2–3.

4 Declaration of John DiDonato in Support of Chapter 11 Petitions and First Day Motions (Main Case Dkt. No. 26) at ¶¶ 8-9. Mr. Owoc included Mr. DiDonato’s Declaration as Exhibit C to Defendant’s Response in Opposition and Cross-Motion for Summary Judgment (Dkt. No. 384) (the “Response”). The Court may take judicial notice of Mr. DiDonato’s Declaration under Federal Rule of Evidence 201. Rule 201(c)(1) provides that the Court may take judicial notice on its own, and the Eleventh Circuit has provided that courts may take judicial notice of their own records. United States v. Rey, 811 F.2d 1453, 1457 n.5 (11th Cir. 1987).

5Declaration of John DiDonato in Support of Chapter 11 Petitions and First Day Motions (Main Case Dkt. No. 26) at ¶ 9.

6Monster Energy Co. v. Vital Pharms., Inc., No. 23-55451 (9th Cir. Apr. 15, 2025) (mem.), at 2.

7Jury Verdict Form, Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.).

8Second Amended Complaint (Dkt. No. 148) at ¶13. director, and Chief Executive Officer at all times relevant to the allegations in Count Three.9 Defendant’s own papers state that VPX had “no corporate will separate from Mr. Owoc’s own.”10 There were no minority shareholders, no independent directors,

and no board other than Mr. Owoc himself.11 In 2018, Monster Energy Company filed suit against both VPX and Mr. Owoc individually in the United States District Court for the Central District of California, alleging that the Super Creatine advertising violated Section 43(a) of the Lanham Act (the “Monster False Advertising Litigation”).12 Following a seven-week jury trial, the jury: (1) found both VPX and Mr. Owoc liable for false advertising; (2) found that

their false advertising was willful and deliberate; and (3) awarded $271,924,174 in damages.13 Monster was additionally awarded approximately $21 million in attorneys’ fees and over $6 million in costs.14 The total judgment—which the Court will refer to as the “False Advertising Judgment”—approached $300 million. The jury was instructed that “VPX and/or Mr. Owoc acted willfully if they knew that their advertising was false or misleading or if they acted with indifference to

9Declaration of John H. Owoc at ¶¶ 2–3.

10Response at 24. Representations in a party’s brief qualify as judicial admissions that can be used against them for purposes of summary judgment. American Title Ins. Co. v. Lacelaw Corp., 861 F.2d 224, 226 (9th Cir. 1988).

11Defendants' Statement of Disputed Material Facts (Dkt. No. 387) ¶¶ 1–2.

12Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.). 13Jury Verdict Form, Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.).

14Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.), Order Denying Motion for New Trial (Dkt. No. 1040), at 31, 33. whether their advertising was false or misleading.”15 This instruction is significant. The jury's willfulness finding necessarily encompassed a determination that Mr. Owoc either knew that the advertising was false or acted with indifference to whether

it was. The district court denied Defendants’ post-trial motions, confirming that the jury “necessarily found that Defendants’ advertising of Super Creatine (1) is false or misleading; (2) deceives or is likely to deceive consumers; (3) is material to consumers’ purchasing decisions; and (4) injured Monster.”16 Mr. Owoc appealed. The Ninth Circuit affirmed, describing the “key issue at trial” as “whether Monster had shown

that Owoc’s advertisement of BANG as containing Super Creatine was false advertising under the Lanham Act.”17 The False Advertising Judgment was one of the principal reasons for VPX’s bankruptcy filing on October 10, 2022.18 Ultimately, a Chapter 11 plan of liquidation was confirmed and became effective on November 21, 2023, establishing the VPX Liquidating Trust,19 which is the Plaintiff in this adversary proceeding. The Trust filed its Motion for Partial Summary Judgment on December 23, 2025, seeking a

15Jury Instructions, Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.), Trial Tr. 28:23–29:5.

16Monster Energy Co. v. Vital Pharms., Inc., No. 5:18-cv-01882-JGB-SHK (C.D. Cal.), Order Denying Motion for New Trial (Dkt. No. 1040), at 18. 17Monster Energy Co. v. Vital Pharms., Inc., No. 23-55451 (9th Cir. Apr. 15, 2025) (mem.), at 5. 18Declaration of John DiDonato in Support of Chapter 11 Petitions and First Day Motions (Main Case Dkt. No. 26) at ¶ 41.

19Second Amended Joint Plan of Liquidation (Main Case Dkt. No. 1905).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Terry Gilmour v. Gates, McDonald & Co.
382 F.3d 1312 (Eleventh Circuit, 2004)
Pepper v. Litton
308 U.S. 295 (Supreme Court, 1939)
Parklane Hosiery Co. v. Shore
439 U.S. 322 (Supreme Court, 1979)
Montana v. United States
440 U.S. 147 (Supreme Court, 1979)
Allen v. McCurry
449 U.S. 90 (Supreme Court, 1980)
Bateman Eichler, Hill Richards, Inc. v. Berner
472 U.S. 299 (Supreme Court, 1985)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Stern v. Marshall
131 S. Ct. 2594 (Supreme Court, 2011)
In Re MDL-1824 Tri-State Water Rights Litigation
644 F.3d 1160 (Eleventh Circuit, 2011)
United States v. William Rey
811 F.2d 1453 (Eleventh Circuit, 1987)
Della-Donna v. Nova University, Inc.
512 So. 2d 1051 (District Court of Appeal of Florida, 1987)
Gracey v. Eaker
837 So. 2d 348 (Supreme Court of Florida, 2002)
Luzinski v. Peabody & Arnold LLP (In Re Gosman)
382 B.R. 826 (S.D. Florida, 2007)
O'Halloran v. Pricewaterhousecoopers LLP
969 So. 2d 1039 (District Court of Appeal of Florida, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
In re: VITAL PHARMACEUTICALS, INC., et al. v. JOHN H. OWOG, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-vital-pharmaceuticals-inc-et-al-v-john-h-owog-et-al-flsb-2026.